Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

ConditionRSV Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-24
SponsorFederico Martinón Torres

About this trial

A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.

Eligibility criteria

Qualifiers

Subjects born in Galicia from April 1st, 2023 and March 1st, 2026

Disqualifiers

No specific criteria has been reported

Trial design

Treatments tested in this trial

  • Nirsevimab

Treatment groups

42,000 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Federico Martinón Torres

Lead sponsor

Hospital Clinico Universitario de Santiago

Sponsor institution